Cargando…
Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects
Recent studies have highlighted the successes of chimeric antigen receptor-modified T- (CART-) cell-based therapy for B-cell malignancies, and early phase clinical trials have been launched in recent years. The few published clinical studies of CART cells in solid tumors have addressed safety and fe...
Autores principales: | Guo, Yelei, Wang, Yao, Han, Weidong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4779545/ https://www.ncbi.nlm.nih.gov/pubmed/26998495 http://dx.doi.org/10.1155/2016/3850839 |
Ejemplares similares
-
Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment
por: Wang, Zhenguang, et al.
Publicado: (2017) -
Targeting cancer stem cells by using chimeric antigen receptor-modified T cells: a potential and curable approach for cancer treatment
por: Guo, Yelei, et al.
Publicado: (2017) -
Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors
por: Zhang, Erhao, et al.
Publicado: (2018) -
Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy
por: Dai, Hanren, et al.
Publicado: (2016) -
PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity
por: Wei, Jianshu, et al.
Publicado: (2019)